small molecule

VYKAT XR

DIAZOXIDE CHOLINE

Loss of exclusivityNovember 2035latest FDA-listed patent expiry

CompanySoleno Therapeutics →View the full company profile on CliffBio

Drug detail

Brand name	VYKAT XR
Active ingredient	DIAZOXIDE CHOLINE
Strength	150MG
Dosage form	TABLET, EXTENDED RELEASE
Route	ORAL
Modality	Small molecule
FDA approval	March 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12343348	November 2035	use U-4211
12178823	November 2035	use U-4167
9757384	November 2035	use U-4167
12419895	November 2035	use U-4275
7799777	March 2029	substance
7572789	December 2026	substance, product

Regulatory exclusivity

Code	Expires
ODE-532	May 2032
NP	March 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Soleno Therapeutics